These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
668 related articles for article (PubMed ID: 11156391)
1. Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis. Ando Y; Saka H; Ando M; Sawa T; Muro K; Ueoka H; Yokoyama A; Saitoh S; Shimokata K; Hasegawa Y Cancer Res; 2000 Dec; 60(24):6921-6. PubMed ID: 11156391 [TBL] [Abstract][Full Text] [Related]
2. Genetic polymorphism in the phenobarbital-responsive enhancer module of the UDP-glucuronosyltransferase 1A1 gene and irinotecan toxicity. Kitagawa C; Ando M; Ando Y; Sekido Y; Wakai K; Imaizumi K; Shimokata K; Hasegawa Y Pharmacogenet Genomics; 2005 Jan; 15(1):35-41. PubMed ID: 15864124 [TBL] [Abstract][Full Text] [Related]
3. Genetic polymorphisms of the UDP-glucuronosyltransferase 1A7 gene and irinotecan toxicity in Japanese cancer patients. Ando M; Ando Y; Sekido Y; Ando M; Shimokata K; Hasegawa Y Jpn J Cancer Res; 2002 May; 93(5):591-7. PubMed ID: 12036456 [TBL] [Abstract][Full Text] [Related]
4. Pharmacogenetic impact of polymorphisms in the coding region of the UGT1A1 gene on SN-38 glucuronidation in Japanese patients with cancer. Araki K; Fujita K; Ando Y; Nagashima F; Yamamoto W; Endo H; Miya T; Kodama K; Narabayashi M; Sasaki Y Cancer Sci; 2006 Nov; 97(11):1255-9. PubMed ID: 16965601 [TBL] [Abstract][Full Text] [Related]
5. [UGT1A1 Genotyping for Proper Use of Irinotecan]. Matsuoka A; Ando Y Rinsho Byori; 2015 Jul; 63(7):876-82. PubMed ID: 26591441 [TBL] [Abstract][Full Text] [Related]
6. Relevance of different UGT1A1 polymorphisms in irinotecan-induced toxicity: a molecular and clinical study of 75 patients. Rouits E; Boisdron-Celle M; Dumont A; Guérin O; Morel A; Gamelin E Clin Cancer Res; 2004 Aug; 10(15):5151-9. PubMed ID: 15297419 [TBL] [Abstract][Full Text] [Related]
7. Polymorphisms of UDP-glucuronosyltransferase and pharmacokinetics of irinotecan. Ando Y; Ueoka H; Sugiyama T; Ichiki M; Shimokata K; Hasegawa Y Ther Drug Monit; 2002 Feb; 24(1):111-6. PubMed ID: 11805731 [TBL] [Abstract][Full Text] [Related]
8. UGT1A1 predicts outcome in colorectal cancer treated with irinotecan and fluorouracil. Wang Y; Shen L; Xu N; Wang JW; Jiao SC; Liu ZY; Xu JM World J Gastroenterol; 2012 Dec; 18(45):6635-44. PubMed ID: 23236239 [TBL] [Abstract][Full Text] [Related]
9. [Study of irinotecan-induced toxicity and its correlation to UGT1A1 gene promoter polymorphisms]. Li H; Huang H; Liu JH Zhonghua Fu Chan Ke Za Zhi; 2011 Dec; 46(12):888-91. PubMed ID: 22333276 [TBL] [Abstract][Full Text] [Related]
10. UGT1A1 promoter genotype correlates with SN-38 pharmacokinetics, but not severe toxicity in patients receiving low-dose irinotecan. Stewart CF; Panetta JC; O'Shaughnessy MA; Throm SL; Fraga CH; Owens T; Liu T; Billups C; Rodriguez-Galindo C; Gajjar A; Furman WL; McGregor LM J Clin Oncol; 2007 Jun; 25(18):2594-600. PubMed ID: 17577039 [TBL] [Abstract][Full Text] [Related]
11. The UGT1A1*28 genotype and the toxicity of low-dose irinotecan in patients with advanced lung cancer. Sugiyama T; Hirose T; Kusumoto S; Shirai T; Yamaoka T; Okuda K; Ohnishi T; Ohmori T; Adachi M Oncol Res; 2010; 18(7):337-42. PubMed ID: 20377135 [TBL] [Abstract][Full Text] [Related]
12. UGT1A1 polymorphism can predict hematologic toxicity in patients treated with irinotecan. Côté JF; Kirzin S; Kramar A; Mosnier JF; Diebold MD; Soubeyran I; Thirouard AS; Selves J; Laurent-Puig P; Ychou M Clin Cancer Res; 2007 Jun; 13(11):3269-75. PubMed ID: 17510208 [TBL] [Abstract][Full Text] [Related]
13. [Relationship between UGT1A1 gene polymorphisms and irinotecan-induced severe adverse events]. Wang XF; Ma C; Gong FF; Yi SY; Xing GC; Wang KJ; Yang Q; Cao W Zhonghua Zhong Liu Za Zhi; 2018 Aug; 40(8):594-599. PubMed ID: 30139029 [No Abstract] [Full Text] [Related]
14. UGT1A1*28 and other UGT1A polymorphisms as determinants of irinotecan toxicity. Biason P; Masier S; Toffoli G J Chemother; 2008 Apr; 20(2):158-65. PubMed ID: 18467239 [TBL] [Abstract][Full Text] [Related]
15. UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity. Iyer L; Das S; Janisch L; Wen M; Ramírez J; Karrison T; Fleming GF; Vokes EE; Schilsky RL; Ratain MJ Pharmacogenomics J; 2002; 2(1):43-7. PubMed ID: 11990381 [TBL] [Abstract][Full Text] [Related]
17. UGT1A1 gene variations and irinotecan treatment in patients with metastatic colorectal cancer. Marcuello E; Altés A; Menoyo A; Del Rio E; Gómez-Pardo M; Baiget M Br J Cancer; 2004 Aug; 91(4):678-82. PubMed ID: 15280927 [TBL] [Abstract][Full Text] [Related]
18. UGT1A1*28 polymorphism predicts irinotecan-induced severe toxicities without affecting treatment outcome and survival in patients with metastatic colorectal carcinoma. Liu CY; Chen PM; Chiou TJ; Liu JH; Lin JK; Lin TC; Chen WS; Jiang JK; Wang HS; Wang WS Cancer; 2008 May; 112(9):1932-40. PubMed ID: 18300238 [TBL] [Abstract][Full Text] [Related]
19. Genotype-directed, dose-finding study of irinotecan in cancer patients with UGT1A1*28 and/or UGT1A1*6 polymorphisms. Satoh T; Ura T; Yamada Y; Yamazaki K; Tsujinaka T; Munakata M; Nishina T; Okamura S; Esaki T; Sasaki Y; Koizumi W; Kakeji Y; Ishizuka N; Hyodo I; Sakata Y Cancer Sci; 2011 Oct; 102(10):1868-73. PubMed ID: 21740478 [TBL] [Abstract][Full Text] [Related]
20. UGT1A1*28 genotype predicts gastrointestinal toxicity in patients treated with intermediate-dose irinotecan. Ferraldeschi R; Minchell LJ; Roberts SA; Tobi S; Hadfield KD; Blackhall FH; Mullamitha S; Wilson G; Valle J; Saunders M; Newman WG Pharmacogenomics; 2009 May; 10(5):733-9. PubMed ID: 19450125 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]